Sponsor Dossier
Recordati Rare Diseases
Sponsor Dossier for Recordati Rare Diseases. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: Carbaglu
- Brand: COSMEGEN
- Brand: CYSTADANE
- Brand: CYSTADROPS
- Brand: ISTURISA
- Brand: PEDEA
- Brand: QARZIBA
- Brand: SIGNIFOR
- Device (sponsor): Subcutaneous/intramuscular injection set, medicated
About
Recordati Rare Diseases is an Australian Private Company with ABN 26627263094, registered in NSW and currently active.
Portfolio
Recordati Rare Diseases has 9 brands on the ARTG, of which 9 are indexable and 9 carry a Product Information document. 4 brands are PBS-listed, 5 have a PBAC outcome on record, and 5 have an AusPAR on record. Notable brands include Carbaglu, COSMEGEN, CYSTADANE, CYSTADROPS, ISTURISA, PEDEA, QARZIBA, SIGNIFOR, SYLVANT.
Therapeutic focus
— Rare Disease: 4 brands — Oncology: 2 brands — Endocrinology: 2 brands — Haematology: 1 brand
PBS footprint
4 brands are PBS-listed, with the latest PBS schedule date 2026-11-01.
Regulatory activity
The latest PBAC outcome is 2024-09-01, across 5 brands with a PBAC outcome on record. The latest AusPAR is 2022-10-27, across 5 brands with an AusPAR on record.